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Abstract
Background: BRCA1 gene-related tumours are more frequently estrogen receptor (ER) and
progesterone receptor (PR) negative with a lower prevalence of human epidermal growth factor
receptor 2 (HER2) overexpression or amplification. We evaluated the effectiveness of a
combination of homogeneously selected criteria and immunohistochemical (IHC) characteristics of
Familial Breast Cancers (FBCs) in detecting BRCA1 mutation carriers.
Methods: Primary breast tumours from 93 FBC patients defined by specific eligibility criteria,
based on personal and familial tumour history, were evaluated by Allred's method. The BRCA1
molecular analysis, including Multiplex Ligation-dependent Probe Amplification (MLPA), was
considered as the gold standard assay.
Results: A total of 10 BRCA1 pathogenetic mutations was found. With the exclusion of the
tumours characterized by double positive receptorial status and/or strong HER2 positivity (3+), we
identified 22 patients, 10 of whom resulted as BRCA1 mutation carriers. The sensitivity, specificity,
positive and negative predictive values were 100%, 83.3%, 45.4% and 100% respectively.
Conclusion: Our findings suggest that the IHC analysis by Allred's method improves our ability to
select patients for BRCA1 testing.
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Background
One of the still unexplained features of BRCA1-mutant
breast tumours is their frequent lack of ER expression; in
fact, up to 90% of these tumours exhibit a loss of ER
expression [1,2]. In addition, BRCA1-associated breast
cancers frequently show a low prevalence of HER2 overex-
pression or amplification [3-5].
Patients with a strong family history of breast and/or ovar-
ian cancer are counselled to receive genetic testing for
mutations in the BRCA1/BRCA2 genes. The selection of
patients is crucial and relies mostly on family history and
phenotype ascertainment [6-8]. In general, only 20-40%
of screened families, even using rigid selection criteria,
have positive mutation results [9,10]. In particular, the
rate of mutations in Italian breast and/or ovarian cancer
families is rather controversial and ranges from 8% to
37% [11]. Moreover, it has been recently pointed out that
only less than 10% of cases with a positive family history
harbour a BRCA1 mutation [12].
In this study, we evaluated the effectiveness of a combina-
tion of selected eligibility criteria and IHC characteristics
of breast cancer to identify patients who have a higher
probability of being BRCA1 mutation carriers.
Methods
From September 2002 to October 2008, a total of 93
female index cases affected with breast cancer complying
with the eligibility criteria for BRCA testing in use at the
Centro di Riferimento Oncologico, National Cancer Insti-
tute, Aviano, Italy were enrolled in the study [13]. Cases
affected with ovarian cancer and male breast cancer were
excluded. Written informed consent for genetic testing
was obtained from all the participants. The study fully
conformed to the Declaration of Helsinki and to the cur-
rent Italian Legislation and was also approved by the Eth-
ical Committee of the Institute.
Genomic DNA was purified from blood samples obtained
from each proband. Screening for mutations in the
BRCA1/BRCA2 genes was carried out by Denaturing High
Performance Liquid Cromatography and direct sequenc-
ing techniques. Primer sequences and PCR conditions
have been previously described [14-16]. Germline rear-
rangements of BRCA1/BRCA2 genes were also analysed by
Multiple Ligation-dependent Probe Amplification
(MLPA). Missense, silent, and intronic mutations, whose
clinical significance have not yet been reported, were clas-
sified as genetic variants of uncertain significance (unclas-
sified variant, uv) in accordance with the BIC database
[17].
Ventana Medical Systems clone 6F11 (Ventana Medical
Systems, Inc., Tucson, AZ) for the evaluation of the ER and
Ventana Medical Systems clone 1E2 for the evaluation of
the PR were used. With the Allred score, the proportion
score (PS) and the intensity score (IS) are assessed in six
and four grades, respectively 0-5 and 0-3, then the total
score is assessed in eight grades (0 and 2-8) [18]. Tumours
with an IHC total score of 3 or more were reported as pos-
itive. The IHC analysis of HER2 was performed by staining
with the rabbit anti-human HER2 antibody clone 4B5
(Ventana Medical Systems). A score index of 0, 1, 2 and 3
was used, corresponding respectively to negative, weak,
moderate and strong staining intensity, and the percent-
age of positive cells at each intensity was estimated subjec-
tively.
The sensitivity, specificity, and positive and negative pre-
dictive values were calculated from the results of the IHC
analysis to predict for BRCA1 mutations.
Results
In total, 19 different BRCA1/BRCA2 deleterious muta-
tions were identified in the 93 unrelated patients. Ten
(10.8%) patients resulted BRCA1 mutation carriers
whereas in nine (9.7%) a BRCA2 mutation was found
(Tables 1 and 2). The prevalence of BRCA1 large genomic
rearrangements accounted for 20% (2/10) of the BRCA1
gene mutation spectrum. No large deletions or duplica-
tions involving the BRCA2 gene were observed. In this
series, all BRCA1 tumours showed a double or a single
negative hormonal receptorial status, whereas HER2 was
invariably negative or only weakly expressed (Table 1).
Altogether, 21 cases showed an uv alteration of BRCA1
and/or BRCA2 genes: 7 BRCA1 uv, 7 BRCA2 uv, 5 cases
with a variant in both genes, 1 triple BRCA1 uv and 1 dou-
ble BRCA2 uv associated with a BRCA1 uv, respectively
(Table 3).
To evaluate the sensitivity and specificity of the IHC
screening in a selected set of patients, the combination
between BRCA1 point mutation screening and MLPA was
considered as the gold standard assay. According to the
receptorial status, patients were divided into two groups.
The first group included all the ER negative and/or PR neg-
ative tumours, whereas the second group consisted of the
double positive ones. The BRCA1/2 negative mutation
group is shown in Table 4.
Twenty-nine tumours did not show a positive staining for
ER and/or PR hormone receptors. Notably, 10 of these
negative cases were from BRCA1 mutation carriers (Table
5). Furthermore, not considering the cases showing a
strong HER2 positivity (3+), the mutation screening could
have been performed in only 22 patients, detecting the
same number of BRCA1 mutations (Table 6).B
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Table 1: BRCA1 group and IHC tumour characteristics.
ID pts Age at 
diagnosis
DNA Mutation effect Grade ° ER (score) ° PR (score) §HER2 ^ BRCAPRO 
BRCA1
^ 
BRCAP
RO 
BRCA2
^ 
BRCAP
RO 
total
*BC and CBC 
cases
*OC 
cases
BR332 42 633delC 233X 3 - (2) - (0) - 0.975 0.013 0.987 1 (27) 2 
(35, 56)
BR334 26 2428C>A S770X 3 - (0) - (0) - 0.658 0.091 0.748 1 (53) 1 (75)
BR341 45 del 9-19 del ex. 9-19 ter 184 3 - (0) - (0) - 0.320 0.524 0.841 3 
(37, 48 M, 52)
/
BR352 37 del 23-24 unpredictable 3 - (0) - (0) 1+ 0.777 0.075 0.850 1 
(29+42 CBC)
/
BR384 50+56 CBC 795delT 233X 3 - (0) - (0) 1+/2+ 0.529 0.085 0.613 2 (56, 57)1  ( 5 7 )
BR386 40 1806C>T Q563X 3 - (0) - (0) 1+/2+ 0.311 0.048 0.358 / 1 (69)
BR392 31 795delT 233X 3 - (0) - (0) - 0.813 0.066 0.876 1 
(46+48 CBC)
/
BR441 46 5181delGTT 1688delV 3 - (0) - (0) - 0.166 0.036 0.202 3 (46, 47, 48) 1 (63)
BR507 22 633delC 233X 3 - (0) - (0) 1+ 0.091 0.015 0.106 / /
BR587 38+60 CBC 300T>G C61G 3 - (0) - (0) 1+ 0.922 0.063 0.984 2 (40, 43)1  ( 6 0 )
BC = breast cancer; CBC = controlateral breast cancer; OC = ovarian cancer; / = no cases; M = male. The ages at diagnosis of the first cousins are in boldface type; ° IHC Allred total scores of 3 
or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO software http://www.isds.duke.edu/~gp/
brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.B
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Table 2: BRCA2 group and IHC tumour characteristics.
ID pts Age at 
diagnosis
DNA Mutation 
effect
Grade ° ER (score) ° PR (score) §HER2 ^ BRCAPRO 
BRCA1
^ BRCAPRO 
BRCA2
^ BRCAPRO 
total
*BC, CBC and 
BBC cases
*OC 
cases
BR288 36 9326insA 3043X 3 + (6) + (5) 1+ 0.003 0.026 0.029 / 1 (44)
BR295 54 657insC 157X 2 + (8) + (5) - 0.029 0.405 0.434 2 
(41+43 CBC, 48)
/
BR312 47 IVS16-2A>G Exon skipping 3 + (5) + (3) 1+ 0.002 0.365 0.367 2 
(47, 77 M)
/
BR342 44+52 CBC 9106C>T Q2960X 3 + (8) + (3) 2+ 0.006 0.182 0.187 2 (59, 68+75 CBC) /
BR360 43 IVS23+1G>T Exon skipping 3 + (4) + (6) 2+/3+ 0.088 0.553 0.640 1 
(30 BBC)
/
BR382 44+63 CBC 7507del7 2168X 3 + (6) + (8) 1+ 0.002 0.061 0.063 1 (35) /
BR410 24 9325delA 3061X 2 + (7) + (4) 1+ 0.170 0.557 0.727 1 (47) 2 
(54, 73)
BR450 48 4450C>T Q1408X 1 + (7) + (7) - 0.010 0.044 0.054 2 (52, 55) 2 
(38, 55)
BR571 31 3036del4 959X 2 + (3) + (6) 3+ 0.001 0.037 0.038 3 
(50, 50, 61)
/
BC = breast cancer; CBC = controlateral breast cancer; BBC = bilateral breast cancer; OC = ovarian cancer; / = no cases; M = male. ° IHC Allred total scores of 3 or more were reported as positive. §HER2 
IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO Software http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family 
and ages of onset in parentheses.B
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Table 3: BRCA1 and/or BRCA2 uv group and IHC tumour characteristics.
ID pts Age at 
diagnosis
DNA Mutation 
effect
Grade ° ER 
(score)
° PR 
(score)
§HER2 ^ 
BRCAPRO 
BRCA1
^ 
BRCAPRO 
BRCA2
^ 
BRCAPR
O total
BC, CBC 
and BBC 
cases
OC cases
BRCA1 uv
BR417 30 1186A>G Q356R 2 + (3) - (0) 3+ 0.015 0.040 0.055 1 (46) /
BR427 48 4274A>G L1385L 2 + (7) + (7) 1+ 0.000 0.010 0.011 1 (44) /
BR437 50 2351T>G A744A 1 + (5) + (3) 1+ 0.000 0.014 0.015 3 (50, 55, 
59)
/
BR523 48 BBC IVS20+60ins
12
2 + (6) + (7) 1+ 0.018 0.245 0.263 3 (50,50, 52)/
BR570 47 5221T>C L1701P 3 - (0) + (3) 3+ 0.094 0.169 0.264 2 (49+52 
CBC, 56)
/
BR647 49 1186A>G Q356R 3 + (8) + (7) 1+ 0.005 0.010 0.015 3 (65, 67, 
70)
/
BR658 43 1186A>G Q356R 3 + (6) + (6) 2+ 0.001 0.069 0.070 3 (50+63 
CBC, 57, 
60*)
/
BR665 65 BBC 655A>G Y179C 2 + (5) + (5) - 0.001 0.004 0.004 3 
(60, 80, 80)
/
1575T>C F486L
1767A>G N550H
BRCA2 uv
BR376 55 IVS2-7T>A 2 + (6) + (3) 1+ 0.000 0.008 0.008 2 
(45, 90)
/
BR390 51 OC+54 
BBC
6328C>T R2034C 2 + (5) + (8) - 0.130 0.648 0.777 3 (34, 39, 
40)
/
BR458 44+49 CBC 5972T>C T1952I 2 + (7) + (5) - 0.025 0.433 0.459 2 (50 BBC, 
70)
/
BR486 56 2457T>C/ 
9329A>G
H743H/
R3034Q
3 + (5) + (8) - 0.000 0.000 0.000 4 (57, 71, 
75, 90)
/B
M
C
 
C
a
n
c
e
r
 
2
0
0
9
,
 
9
:
3
6
0
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
0
7
/
9
/
3
6
0
P
a
g
e
 
6
 
o
f
 
1
2
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
BR505 67 6751C>G Q2175E 1 + (7) + (7) - 0.018 0.426 0.444 4 (40 BBC, 
50 BBC, 53 
BBC, 58)
/
BR538 62 4236G>A L1356L 2 + (7) + (7) - 0.001 0.025 0.026 2 (50 BBC, 
56)
/
BR587 38+60 CBC IVS24-
113T>G
3 - (0) - (0) 1+ 0.922 0.063 0.984 2 (40, 43)1  ( 6 0 )
BRCA1/2 
uv
BR514 57 3238G>A S1040N 1 + (7) + (8) - 0.001 0.061 0.062 4 (42, 45, 
49, 55)
/
IVS4+67A>
C
1613A>G
E462G
BR552 70 4158A>G R1347G 3 + (5) + (3) 3+ 0.000 0.012 0.012 3 
(40, 47, 65)
/
6328C>T R2034C
BR567 50 IVS4+67A>
C
3 + (6) + (7) - 0.009 0.215 0.225 3 (37 BBC, 
50 BBC, 50)
1 (59)
2457T>C H743H
BR571 31 IVS9-34T>C 2 + (3) + (6) 3+ 0.001 0.037 0.038 3 (50, 50, 
61)
/
5972C>T T1951M
BR580 43 3238G>A S1040N 3 + (7) + (5) 1+ 0.001 0.030 0.031 2 
(46, 68)
/
1409A>G E394A
BR640 30 855T>G L246V 3 + (7) - (0) 1+ 0.117 0.261 0.378 2 
(30, 40)
/
4296G>A L1356L
BC = breast cancer; CBC = controlateral breast cancer; BBC = bilateral breast cancer; OC = ovarian cancer; / = no cases; M = male. The ages at diagnosis of the first cousins are in boldface type; 
° IHC Allred total scores of 3 or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO software 
http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.
Table 3: BRCA1 and/or BRCA2 uv group and IHC tumour characteristics. (Continued)B
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Table 4: non BRCA1/2 mutation group and IHC tumour characteristics.
ID pts Age at 
diagnosis
Grade ° ER (score) ° PR (score) §HER2 ^ BRCAPRO 
BRCA1
^ BRCAPRO 
BRCA2
^ BRCAPRO 
total
*BC, CBC and 
BBC cases
*OC cases
BR271 40 G2 + (7) + (5) 1+/2+ 0.002 0.036 0.038 1 (37) /
BR275 28 BBC G3 + (7) + (7) - 0.067 0.578 0.645 1 (55) /
BR281 42 G3 + (6) + (4) 3+ 0.008 0.222 0.230 6 (27, 36, 50, 60, 50 
BBC, 60)
/
BR297 54 G3 - (0) - (0) - 0.064 0.018 0.081 2 (42, 69) /
BR304 41 G3 + (7) + (6) - 0.002 0.058 0.060 2 (52, 64) /
BR315 46 BBC G2 + (7) + (7) 1+ 0.012 0.160 0.172 1 (49) /
BR335 64 G2 + (8) - (0) 1+ 0.002 0.017 0.020 2 (57, 70) 1 (69)
BR338 36 G3 - (0) - (0) 3+ 0.131 0.029 0.160 2 (45, 71) /
BR339 74 G2 + (7) + (7) - 0.003 0.085 0.088 3 
(39, 61+63 CBC, 
66)
2 (54, 64)
BR340 35 G3 + (7) - (0) 3+ 0.009 0.026 0.035 2 (43, 59) /
BR348 55 G3 + (7) - (0) 1+ 0.009 0.062 0.071 2 (56, 56) 1 (68)
BR350 42 G3 + (7) + (7) 2+ 0.001 0.014 0.015 4 
(49, 57, 61*, 70*)
/
BR357 35 G3 + (6) - (0) - 0.002 0.014 0.016 2 (55, 67) /
BR377 46 G3 + (7) + (6) - 0.000 0.007 0.007 2 (46, 70) /
BR380 30 G2 - (0) - (0) 1+/2+ 0.303 0.067 0.370 3 (42, 64, 64) /
BR381 45 G3 + (5) + (6) - 0.000 0.004 0.004 2 (45, 85) /
BR398 50 G2 + (5) + (3) - 0.000 0.020 0.020 5 
(60, 61, 65, 70, 98)
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BR403 53+57 CBC G3 + (7) + (7) - 0.000 0.006 0.007 1 
(82+84 CBC)
/
BR408 53 G2 + (6) + (4) - 0.000 0.002 0.002 3 
(71*, 85*, 67°)
/
BR414 60 G2 - (2) + (4) - 0.003 0.101 0.104 2 (73M, 50) /
BR418 27 G3 - (0) - (0) 3+ 0.093 0.015 0.108 / /
BR422 55 G3 + (6) - (2) - 0.002 0.014 0.016 2 (50, 53) /
BR424 45 G2 + (5) + (7) 2+ 0.006 0.113 0.119 1 
(49+59 CBC)
/
BR425 27 G2 + (3) + (5) 3+ 0.001 0.012 0.013 / /
BR439 52 G3 - (0) - (2) - 0.052 0.030 0.082 3 (36, 60, 70) 1 (78)
BR445 54 G1 + (6) + (3) 1+ 0.004 0.067 0.072 2 (45, 48+52 CBC) /
BR446 50 G2 + (7) + (4) 1+ 0.000 0.008 0.008 1 (40) /
BR447 65 G2 + (8) + (6) - 0.001 0.045 0.046 2 (58, 79) /
BR449 50 G2 + (6) + (7) - 0.001 0.020 0.021 1 (37) /
BR457 53 G3 + (4) - (2) 3+ 0.000 0.003 0.004 2 (55, 55) /
BR463 48 G3 + (6) + (5) - 0.001 0.032 0.033 1 (67 BBC) /
BR480 53 G2 + (7) + (7) - 0.004 0.135 0.139 3 (31, 50, 53) /
BR484 57 G2 + (7) + (7) 1+ 0.000 0.014 0.014 2 
(55, 73+78 CBC)
/
BR494 58 G3 + (5) - (0) - 0.020 0.352 0.372 4 
(40, 43, 45, NA M)
/
BR498 46 G2 + (5) + (7) - 0.005 0.837 0.841 4 
(42 BBC, 48, 49M, 
74)
/
BR506 55 G1 - (0) + (5) - 0.000 0.012 0.012 3 (62, 30, 76) /
Table 4: non BRCA1/2 mutation group and IHC tumour characteristics. (Continued)B
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BR535 56 G3 + (7) + (7) 1+ 0.000 0.019 0.019 3 (47, 53, NA) /
BR542 45 G3 + (7) + (7) 1+ 0.007 0.112 0.119 2 (36,62) /
BR545 63 G2 + (7) + (6) 1+ 0.000 0.003 0.003 2 (64, 70) /
BR549 36 G3 + (6) + (5) 1+ 0.013 0.142 0.155 1 (36) /
BR553 54 G2 + (7) + (6) 1+ 0.011 0.486 0.497 2 (49, 65) 1 (55)
BR558 45 G1 +(7) + (8) 1+ 0.000 0.029 0.030 3 (48, 78, 78) /
BR560 78 G2 + (7) + (3) 1+ 0.000 0.025 0.025 3 (45, 48, 78) /
BR569 41 G2 + (7) + (8) - 0.114 0.072 0.185 / 2 (60, 60)
BR582 27 G3 + (6) + (8) - 0.001 0.016 0.016 / /
BR584 42 / + (5) + (6) 1+ 0.001 0.017 0.018 3 (40, 54, 69) /
BR592 67 G2 +(7) +(7) 2+ 0.001 0.035 0.036 4 
(48, 52, 55, 60)
/
BR593 48 G3 +(7) + (3) 1+ 0.088 0.242 0.330 3 
(33 BBC, 65, 70)
1 (24)
BR599 39+44 CBC G3 + (6) - (0) 3+ 0.187 0.370 0.557 2 (44, 60) /
BR603 40 G2 + (7) + (7) - 0.001 0.032 0.033 1 (36) /
BR615 49 G1 + (7) + (7) 1+ 0.000 0.004 0.004 2 (49, 50) /
BR649 80 G2 + (7) + (6) 1+ 0.001 0.404 0.406 2 (31, 44 BBC) /
BR650 47 G3 + (6) - (0) - 0.004 0.017 0.021 1 (45) /
BR656 43 G2 + (6) + (7) 1+ 0.003 0.269 0.272 3 (40, 44, 52) /
BR666 56 G2 + (8) + (6) 1+ 0.132 0.201 0.332 3 (39, 50, 51) 3 
(49, 54, 61)
BC = breast cancer; CBC = controlateral breast cancer; OC = ovarian cancer; / = no cases; M = male. The ages at diagnosis of the first cousins are in boldface type; ° IHC Allred total scores of 3 
or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO software http://www.isds.duke.edu/~gp/
brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.
Table 4: non BRCA1/2 mutation group and IHC tumour characteristics. (Continued)BMC Cancer 2009, 9:360 http://www.biomedcentral.com/1471-2407/9/360
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The detection rate of BRCA1 mutations was shown to
increase from 10.8% (10/93) to 45.5% (10/22), thus
allowing the minimization of the number of patients who
should undergo BRCA1 mutation screening.
Discussion
BRCA1-associated tumours have a high probability of
being ER negative (up to 90%), PR negative (79%) and
with a low frequency of HER2 expression [4,5,19-21].
Physical co-deletion of BRCA1 and HER2 loci on chromo-
some 17q, occurring as a second somatic inactivating hit,
may be at least partly responsible for the low incidence of
HER2 expression oramplification in BRCA1-associated
carcinomas [22-24].
In the present series, four of the five triple negative
tumours (80%) harboured BRCA1 mutations. Consist-
ently with these data, the screening carried out by
Musolino et al detected 10 BRCA1 mutations: seven of the
eight IHC evaluated BRCA1-related tumours had a triple
negative phenotype (87%) and all were negative for HER2
expression [25].
We report an overall prevalence of BRCA1 mutations of
10.8% (10/93). The FBC screening procedure based on
the selection of women who were ER and/or PR negative
and with weakly expressed HER2, showed a sensitivity in
BRCA1 mutation carriers of 100% and a specificity of
83.3%, with a positive predictive value of 45.4% and a
negative predictive value of 100%. Moreover, all BRCA1
mutation carriers were identified by using IHC screening,
thus confirming that the Allred's method can be used to
accurately predict the probability of being a carrier of the
BRCA1 mutation.
The IHC test has a very high sensitivity and specificity, and
may substantially improve the detection of BRCA1 patho-
genetic mutations in families with hereditary breast can-
cer.
It has been suggested that the IHC analysis of ER may be
a new powerful predictor of the BRCA1 mutation status.
Estimations show that the probability of being a BRCA1-
mutation carrier in a woman with FBC diagnosed before
the age of 35 years with a grade 3 tumour and ER negative
status is 25%. However, the probability falls to only 5% if
the tumour is ER positive [1,5].
The immunophenotypic features of breast carcinomas
arising in BRCA1 mutation carriers have also been evalu-
ated by Palacios et al, showing that only 25% of BRCA1-
associated tumors were ER positive and PR negative,
whereas all cases were HER2 negative [24].
It should be taken into account, however, that the use of
IHC screening to select cases for BRCA1 mutational anal-
ysis may have some limitations. In fact, although the
majority of BRCA1-mutant tumours lack ER expression,
several studies have shown that a small number retain ER
positivity [26,27]. In addition, whereas the ER negative
status is a highly sensitive predictor (ER-positive cases are
Table 5: Relation between breast cancer receptorial status and BRCA1 mutant genotype.
Receptorial status BRCA1 carriers non-BRCA1 cases Total
° ER- and/or PR- 10 19 29
ER+/PR+ - 64 64
Total 10 83 93
Sensitivity 100%; Specificity 77.1%; Predictive Positive Value 34.4%; Predictive Negative Value 100%; ° IHC Allred total scores of 3 or more were 
reported as positive.
Table 6: Relation between breast cancer receptorial status and BRCA1 mutant genotype excluding HER2 3+ cases.
Receptorial status BRCA1 carriers non-BRCA1 cases Total
° ER- and/or PR- 10 12 22
ER+/PR+ - 60 60
Total 10 72 82
Sensitivity 100%; Specificity 83.3%; Predictive Positive Value 45.4%; Predictive Negative Value 100%; ° IHC Allred total scores of 3 or more were 
reported as positive.BMC Cancer 2009, 9:360 http://www.biomedcentral.com/1471-2407/9/360
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rarely BRCA1 mutation carriers), this parameter has a lim-
ited specificity [1].
In this series of selected patients, a high prevalence of
BRCA1 pathogenetic mutations was observed in FBCs
with double or single negative receptorial status, showing
that the evaluation of IHC characteristics can be useful not
only for therapeutic purposes, but also for the identifica-
tion of a subgroup of patients having a higher probability
of being carriers of BRCA1 deleterious mutations. Further-
more, the evaluation of HER2 expression may also allow
for a reduction of the number of patients who should
undergo BRCA1 mutation screening.
Conclusion
The IHC analysis by Allred's method, a rapid and easily
performed test, can be used before performing expensive
mutation screening in order to select the high-risk cases
who are most likely to carry a deleterious BRCA1 muta-
tion. In patients selected by family history, the analysis of
the cancer IHC phenotype allows the prediction of the
BRCA1 genotype with a very high sensitivity and specifi-
city.
About 90% of BRCA1 related cancers are ER negative and/
or PR negative with weak HER2 expression [4,5,19-21].
Although the IHC evaluation successfully allowed the
limitation of the number of patients to be molecularly
tested, a small proportion of cases carrying the BRCA1
mutations retained the ER expression.
Interestingly, our data confirm that the incidence of
BRCA1 mutations in the ER and/or PR positive cancers is
low. On these grounds, our combined selection approach
could significantly reduce the number of patients who
should undergo BRCA1 mutational analysis, with the pos-
sible limitation of missing one true BRCA1 mutation car-
rier every 100 patients selected by breast cancer familial
history alone. Analysis of a larger series of cases is however
required to validate the proposed selection approach.
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